- ana.catalan@universidadeuropea.es
- Facultad de Ciencias de la Salud - Valencia
Profesor adjunto
Dra. Ana Catalán Latorre
- Biomédicas y Salud
- Fisioterapia
Doctora en Farmacia por la Universidad de Valencia y Doctora en Ciencias de la Vida y del Ambiente por la Universidad de Cagliari. Ha trabajado como Investigadora en la Università degli Studi di Cagliari (Italia) y en Envigo(Anapharm, Barcelona) como Directora de Estudio en el departamento de Drug Metabolism PK/PD. Desde febrero de 2017 hasta la actualidad trabaja en la Unidad de Farmacoterapia Personalizada de la Plataforma de Oncología del Hospital Quironsalud Torrevieja, unidad pionera en España donde se analiza el comportamiento de los fármacos antineoplásicos. Ejerce como docente en grados de la Universidad Europea y en la Universidad de Valencia. Posee una dilatada experiencia en formulación, bioanálisis y monitorización de fármacos. Acreditada por la ANECA de Profesora Ayudante Doctor y con 18 artículos científicos publicados (Q1-Q3). Su labor combina docencia e investigación, con especial interés en la innovación aplicada a las ciencias de la salud y la formación sanitaria.
Formación académica
Doctorado en ciencias de la Ciencias de la Vida, la Tierra y el Fármaco
- Università degli Studi di Cagliari (Italia)
- 2015-2018
Doctorado en farmacia y Tecnología Farmacéutica
- Universitat de València
- 2010-2014
Máster Universitario Investigación y Uso Racional del Medicamento
- Universitat de València
- 2009-2010
Licenciatura en Farmacia
- Universitat de València
- 2003-2008
Experiencia profesional
Titulaciones
Publicaciones
Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study
Evaluation of TDM of TKIs in routine clinical practice through studying the variability in exposure to erlotinib, imatinib, lapatinib, and sorafenib and dose adjustment conducting a retrospective study involving patients who received treatment with TKIs, guided by TDM and with recommendation of dose adjustment. All drugs show large inter-individual variability in exposure. TDM entails a significant improvement in exposure and enables more effective and safe use of TKIs in clinical practice.
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RB1&TP53 co-alterations are strongly associated with genomic biomarkers of response to ICIs in MIBCs:Samples with co-altered RB1&TP53: were enriched in immunity effectors (CD8 cytotoxic lymphocytes, NK cells) and display higher scores of a T cell inflamed signature; have a higher TMB, higher number of SNV predicted neoantigens and higher TILs fractions; have a higher number of DDR mutated and deep deleted DDR genes; have DNA somatic signatures 2 and 13 related to APOBEC mutagenesis.
Nutriosomes: prebiotic delivery systems combining phospholipids, a soluble dextrin and curcumin to counteract intestinal oxidative stress and inflammation
Nutriosomes, new phospholipid nanovesicles, were fabricated in a one-step, organic solvent-free procedure. All the vesicles were small in size, negatively charged, and self-assembled predominantly in unilamellar vesicles. Tthese innovative vesicles showed promising efficacy in vivo, as they improved the bioavailability and the biodistribution of both curcumin and dextrin upon oral administration, which acted synergically in reducing colonic damage chemically induced in rats.
Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin
This work aimed at finding an innovative vesicle-type formulation able to improve the bioavailability of curcumin upon oral administration. The achivement of an enhanced accumulation of curcumin provided by the eudragit-hyaluronan immobilized vesicles, together with an increase in Caco-2 cell viability exposed to hydrogen peroxide, indicated that vesicles can ensure a local protection against oxidative stress and an increase in its intestinal absorption.